Stock AFFYMAX, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Affymax, Inc. Share Price Nasdaq

Equities

US00826A1097

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Affymax, Inc.
2014 Affymax, Inc. Declares Special Cash Distribution, Payable on or About December 23, 2014; Appoints Jonathan M. Couchman as Class I Director, President and Chief Executive Officer CI
2014 Affymax Seeks Acquisitions CI

Financials

Sales 2012 9.44Cr 786.43Cr Sales 2013 13.69L 11Cr Capitalization 2.92Cr 243.69Cr
Net income 2012 -9.3Cr -775.02Cr Net income 2013 -1.4Cr -116.67Cr EV / Sales 2012 6.75 x
Net cash position 2012 6.91Cr 576.16Cr Net cash position 2013 55.97L 47Cr EV / Sales 2013 17.3 x
P/E ratio 2012
-7.39 x
P/E ratio 2013
-2.03 x
Employees -
Yield 2012 *
-
Yield 2013
-
Free-Float 100%
More Fundamentals * Assessed data

Latest news about Affymax, Inc.

Affymax, Inc. Declares Special Cash Distribution, Payable on or About December 23, 2014; Appoints Jonathan M. Couchman as Class I Director, President and Chief Executive Officer CI
Affymax Seeks Acquisitions CI
Affymax, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2014 CI
Affymax Terminates Omontys' Product Collaboration and License Agreement with Takeda Pharmaceutical Company, Effective September 10, 2014 CI
Affymax and Takeda Announce Termination of Omontys(R) (peginesatide) Product Collaboration and License Agreement CI
Affymax To Review Strategic Options CI
Affymax, Inc. Auditor Raises 'Going Concern' Doubt CI
Affymax, Inc. Executes a Seventh Amendment to Lease Agreement CI
Affymax, Inc. Announces Management Changes CI
Affymax, Inc.(OTCPK:AFFY) dropped from NASDAQ Composite Index CI
Affymax, Inc.(OTCPK:AFFY) dropped from NASDAQ Biotechnology Index CI
Affymax, Inc. to Terminate John Orwin as Chief Executive Officer After May 15, 2013 CI
Affymax, Inc. to Reduce Workforce Amid Product Investigation CI
Affymax, Inc. Enters into a Letter Agreement with Oxford Finance Corporation and Silicon Valley Bank CI
Affymax, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2012 CI
More news

Company Profile

Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
Sector
Biotechnology & Medical Research
More about the company

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+19.41% 4.55TCr
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.62% 3.85TCr
LONZA GROUP AG Stock Lonza Group AG
+38.65% 3.81TCr
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+26.95% 3.07TCr
CELLTRION, INC. Stock Celltrion, Inc.
-13.50% 2.6TCr
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.74% 2.59TCr
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.87% 1.41TCr
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+34.36% 1.27TCr
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.14% 1.13TCr
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AFFY Stock
  4. Stock